Clinical Cancer Research, Vol 1, Issue 12 1487-1493, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)

P LoRusso, BJ Foster, E Poplin, J McCormick, M Kraut, L Flaherty, LK Heilbrun, M Valdivieso and L Baker
Department of Internal Medicine, Division of Hematology/Oncology, Wayne State University, Harper Hospital, Detroit, Michigan 48201, USA.

The pyrazoloacridine (PZA) analogue NSC366140 (PD115934) entered clinical trial based on unique preclinical characteristics including solid tumor selectivity in vitro, marked antitumor activity in vivo against murine solid tumors, selectivity against noncycling cells, and activity against multidrug-resistant tumor cells. After identification of the pre-clinical efficacy and an acceptable toxicity profile, a Phase I study of PZA was carried out. A total of 28 patients was entered and received a total of 67 treatment courses. The drug was administered via a 1-h infusion every 21 days. The starting dose was 30 mg/m2 with 2-fold dose escalations through 480 mg/m2. The next dose escalation was 50%, to 720 mg/m2. Grade I through grade IV toxicities were observed. Since no dose-limiting toxicities were observed at 480 mg/m2, and up to grade IV toxicities were observed at 720 mg/m2, an intermediate dose, 600 mg/m2, was evaluated. Dose-limiting toxicities at 720 mg/m2 were hematological (grade III and IV neutropenia) in four of six patients and neurological (up to grade III cerebral toxicities, including restlessness, dizziness, agitation/anxiety, personality changes, and nightmares, as well as myoclonus) in three of six patients treated. The pharmacokinetic parameters which helped predict these toxicities included area under the curve and peak plasma level. Pharmacokinetic studies showed interpatient variations in all parameters studied. The mean area under the curve levels of PZA at the highest two dose levels in patients were near the level detected in mice at their maximum tolerated total dose. The recommended starting dose for Phase II trials using this schedule is 600 mg/m2.

This article has been cited by other articles:

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				J. M. Reid, D. L. Walker, J. K. Miller, L. M. Benson, A. J. Tomlinson, S. Naylor, A. L. Blajeski, P. M. LoRusso, and M. M. Ames The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes Clin. Cancer Res., February 15, 2004; 10(4): 1471 - 1480. [Abstract] [Full Text] [PDF]

				Y. Hu, A. Krishan, W. Nie, K. S. Sridhar, L. D. Mayer, and M. Bally Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells Clin. Cancer Res., February 1, 2004; 10(3): 1160 - 1169. [Abstract] [Full Text] [PDF]

				N. Keshelava, D. Tsao-Wei, and C. P. Reynolds Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53 Clin. Cancer Res., August 1, 2003; 9(9): 3492 - 3502. [Abstract] [Full Text] [PDF]

				J. L. Grem, N. Harold, B. Keith, A. P. Chen, V. Kao, C. H. Takimoto, J. M. Hamilton, J. Pang, M. Pace, G. B. Jasser, et al. A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients Clin. Cancer Res., July 1, 2002; 8(7): 2149 - 2156. [Abstract] [Full Text] [PDF]